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Summary 
Injury to cardiac myocytes often leads to the production of anti-myosin antibodies. While these 
antibodies are a marker of myocardial injury, their contribution to pathogenesis in diseases such 
as autoimmune myocarditis or rheumatic fever is much less dear. We demonstrate in this report 
that monodonal anti-myosin antibodies can mediate myocarditis in a susceptible mouse strain. 
Additionally, we show disease susceptibility depends on the presence of myosin or a myosin-like 
molecule in cardiac extraceUular matrix. This study demonstrates that susceptibility to autoimmune 
heart disease depends not only on the activation of self-reactive lymphocytes but also on genetically 
determined target organ sensitivity to autoantibodies. 
M 
Yocardial injury associated with myocyte necrosis leads 
to the transient activation of heart-reactive immune 
cells (1-3), including anti-myosin-producing B calls (1-3). 
In several pathologic conditions, anti-myosin antibodies have 
been considered a marker for myocyte damage rather than 
a contributor to ongoing tissue injury (1-3). Whereas a direct 
role of these autoantibodies in the pathogenesis of rheumatic 
fever has been proven (4-6), there has been some controversy 
regarding their role in the pathogenesis of autoimmune myo- 
carditis.  Autoimmune myocarditis can be induced in mice 
by infecting susceptible  strains  with  Coxsackie B3  (CB3) 
virus (7-9) or by immunization with cardiac myosin (10). 
After viral infection, all mouse strains develop an early viral 
myocarditis, but some strains progress to a chronic inflam- 
matory cell infiltrate and myocyte necrosis associated  with 
the induction of heart-reactive antibodies and T cells (10-13). 
A dominant self-antigen in this response is cardiac myosin 
heavy chain alpha (myhca)  1 (11). Neu et al. (14) showed that 
the myocarditis developed by susceptible mice is histologically 
similar whether induced as postviral autoimmune myocar- 
ditis or after immunization with cardiac myosin. Whereas 
it has been possible  to demonstrate that mice that develop 
myocarditis have high titers of anti-myosin antibody, it has 
not been possible  to transfer disease to naive mice by trans- 
ferring serum from diseased  animals (14,  15). In addition, 
there are no reports of attempts to induce disease with pas- 
sive transfer of monoclonal anti-myosin antibodies. 
Both DBA/2 and BALB/c mice develop autoimmune myo- 
carditis  after  CB3  virus  infection  or  immunization  with 
1 Abbreviations  used in this paper: myhca, cardiac myosin heavy  chain alpha; 
TBM, antitubular basement membrane. 
cardiac myosin, but recent studies suggest that the mode of 
tissue damage may differ between these two strains (16, 17). 
Whereas anti-myosin antibodies are present at high titer in 
BALB/c mice, they do not appear to contribute significantly 
to pathogenesis (15-18).  In fact, T  cells alone can transfer 
myocardial inflammation and necrosis to BALB/c mice. In 
contrast,  complement depletion in DBA/2  mice causes  a 
marked diminution of inflammation and necrosis (16, 17), 
suggesting that antibody-mediated tissue damage contributes 
to the disease process. 
In an effort to explore why anti-myosin antibodies con- 
tribute to pathogenesis only in DBA/2 mice, we have studied 
the serum anti-myosin response in both DBA/2 and BALB/c 
mice and have examined the effect of administration of mono- 
clonal anti-myosin antibodies in both mouse strains. 
Materials and Methods 
Animals 
All animals were treated according to institutional guidelines. 
BALB/c, DBA/2, A.CA, and CAJ/F1 mice were purchased from 
The Jackson Laboratory (Bar Harbor, ME) and maintained at the 
Albert Einstein College of Medicine animal facility. SCID mice 
were obtained from the breeding colony maintained at the Albert 
Einstein College of Medicine. 
Antigens 
Mouse cardiac myosin was purified from BALB/c mouse hearts 
according to the method of Pollack et al. (18). The purity of the 
preparations  was determined by SDS-PAGE. The myosin concen- 
tration was determined spectrophotometricaUy  using an extinction 
coefficient  of 5.4.  Myosin  was  dissolved  in  50  mM  sodium 
pyrophosphate buffer,  pH 7.2,  and stored at  -70~ 
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A.CA, BALB/c, and DBA/2 mice was injected subcutaneously 
with 100/xg cardiac myosin emulsified in CFA and boosted with 
the same 1 wk later. Mice with the highest titer of anti-myosin 
reactivity were chosen for B cell fusion. These mice received a final 
intravenous or intrasplenic  injection of 100 #g of cardiac myosin 
in PBS and 3 d later, the spleen cells were harvested for fusion. 
ELISAs 
Serum  was  obtained by retro-orbital puncture  of metafane- 
anesthetized mice and stored at  -70~  For analysis by ELISA, 
sera were diluted in PBS-0.5% BSA (Boehringer Mannheim, Indi- 
anapolis, IN). Sera from immunized mice and hybridomas super- 
natants were tested for IgG antibodies to mouse cardiac myosin 
by ELISA as described by Neu et al. (10). Briefly, 100/xg/ml of 
myosin in coating buffer (sodium carbonate, sodium bicarbonate 
buffer, and sodium pyrophosphate, pH 9.6) was adsorbed to mi- 
crotiter plates  (Falcon, Lincoln Park, NJ), blocked with PBS-2% 
BSA, and then incubated with serial dilutions of sera from im- 
munized mice or with culture supernatant. Anti-myosin antibodies 
were detected with pernxidase-conjugated  anti-mouse IgG diluted 
1:1,000 (Sigma Chemical Co., St. Louis, MO) and substrate,  2,2,-, 
azino-di-3-ethylbenzthiazoline sulfonate (Kirkegaard & Perry Lab- 
oratories,  Inc., Gaithersburg, MD).  Optical density was read at 
405 nm on an ELISA reader. Isotype-specific peroxidase conjugated 
anti-mouse IgG (Sigma Chemical Co.) was used in some assays. 
To determine epitope specificity of serum anti-myosin antibodies, 
10 #g/ml of mouse cardiac  myosin fragments in coating buffer 
was adsorbed to microtiter plates (Falcon) at 37~  for 1 h. The 
plates were dried at room temperature overnight. After a blocking 
step with PBS-5% milk (Bio-Rad Laboratories,  Richmond, CA) 
at 37~  for 1 h,  the wells were incubated with sera (1:500 in 
PBS-0.5% BSA) at 37~  for 1 h. After washing, peroxidase-coupled 
anti-mouse IgG (1:1,000; Sigma Chemical Co.) was added at 37~ 
for 1 h. Plates were washed and substrate,  2,2-,azino-di-3-ethyl- 
benzthiazoline sulfonate was added.  Optical density was read at 
405 nm on an ELISA reader. 
Cell Fusion 
B cell hybridomas were obtained by fusion of spleen cells to 
the nonproducing myeloma cell line NSO using standard fusion 
technology (19). Cells were cultured at 370C in HAT medium at 
2  ￿  10  s myeloma cells per ml. Cells from wells with anti-myosin 
reactivity were cloned on soft agar and individual colonies picked 
and rescreened  for production of anti-myosin antibody. 
Characterization of Monoclonal Antibodies 
Isotype of Anti-myosin Antibodies.  Goat anti-mouse Ig specific 
for different classes and subclasses (1:1,000 in PBS; Fisher Biotech, 
Pittsburgh, PA) were adsorbed to 96-well microtiter plates at 37~ 
for 2 h. After blocking with PBS-2% BSA at 4~  overnight, hy- 
bridoma supernatants were incubated in the wells for 2 h at 37~ 
and washed. Anti-class- or subclass-specific goat anti-mouse anti- 
bodies were then conjugated to alkaline phosphatase (1:1,000; Sigma 
Chemical Co.) at 37~  for 1 h. After washing, the phosphatase 
substrate  was added  and the assay read at 405 nm on an ELISA 
reader (Bio-Rad Laboratories). 
Epitope  Mapping on Anti-myosin  Antibodies.  Fragments of BALB/c 
mouse myhca were displayed in a 5% SDS-PAGE minigel. Proteins 
were transferred to nitrocellulose (Schleicher & Schuell, Inc., Keene, 
NH). The membranes were blocked with PBS-5% milk for 1 h 
at room temperature. Strips were incubated with monoclonal anti- 
myosin antibodies (5-10 #g/ml in PBS) overnight at 4~  and washed 
with PBS-0.05% Tween 20.  Immune complexes were developed 
using a peroxidase-labeled  goat anti-mouse IgG (Sigma Chemical 
Co.) at 370C for I h (or 2 h at room temperature). After washing, 
the blot was developed with substrate (ECL Western blotting de- 
tection system, Amersham International, Amersham, Bucks, UK). 
Pathogenicity of Anti-myosin  Antibodies 
Purification  of Monoclonal Anti-myosin Antibodies.  CAF1/J mice 
were injected intraperitoneally with 0.5 ml 2,6,10,14 Tetramethyl- 
pentadecane 98% (Aldrich Chemical Co., Inc., Milwaukee,  WI). 
I wk later, the mice were again injected with 2,6,10,14 Tetramethyl- 
pentadecane.  2 d later, each mouse was injected with 107 mono- 
clonal anti-myosin antibody secreting hybridoma cells in saline. For 
hybridomas generated from A.CA and DBA/2 mice, mice were 
irradiated with 600 rad. The anti-myosin antibody-containing as- 
cites was collected and stored at  -20~ 
Anti-myosin antibodies  of the IgG isotype were purified from 
ascites fluid by 50% ammonium sulfate (pH 7.2) precipitation at 
4~  overnight. The precipitated IgG was dissolved in 5-10 ml PBS, 
then passed (0.8 ml/min) through a protein G-Sepharose column 
in a fast performance liquid chromatography (FPLC) system. Bound 
protein was eluted with 0.1 M glycine, pH 2.7, at 1 ml/min and 
collected  in a neutralizing buffer (2 M  Tris-HC1,  pH 8.0). 
The purity of IgG antibodies was checked by SDS-PAGE under 
reduced and nonreduced conditions. The concentrations of anti- 
myosin  antibodies were measured using an ELISA for IgG. 
Induction of Myocarditis by Anti-myosin Antibodies.  Each mouse 
was injected intraperitoneally with purified anti-myosin antibody, 
100/xg in 200 #1 PBS daily, 5 d a week for 3 wk. Mice were killed 
after 3 wk and the hearts were rapidly excised and placed into 10% 
buffered formalin. 
Histologic Analysis 
Formalin-fixed  hearts were embedded in paraffin according to 
standard procedures.  Sections were prepared from hearts dissected 
in the atrial-apical  axis,  thereby producing two halves in which 
all four chambers could be seen. Three levels, each ,-5 #m in thick- 
ness, were prepared and stained with hematoxylin-eosin. Sections 
were evaluated  from all hearts by S. Factor who was blinded to 
the immunization status  of each animal.  Each heart section was 
examined  for active myocarditis,  its extent and localization. The 
diagnosis of myocarditis is an inflammatory infiltrate associated with 
myocyte necrosis or damage.  The presence of interstitial myocar- 
dial inflammation without necrosis,  so-called borderline myocar- 
ditis,  was  also noted. 
lmmunocytoc  hemistry 
Serially cut, 5-#M-thick sections of formaldehyde-fixed, paraffin- 
embedded tissue were deparaffinized and rehydrated, then blocked 
with 2% horse serum (Vecta stain ABS Kit; Vector Laboratories 
Inc., Burlingame, CA) in PBS in moist chambers.  After blocking, 
the sections  were incubated with biotinylated antibody against 
motise IgG (1:800 for 1 h at room temperature). After washing, 
sections were incubated with alkaline phosphate-labeled ABC re- 
agent (Vecta stain  ABC Kit), washed,  and developed with sub- 
strate  for  streptavidin-alkaline  phosphatase  (BCIP  [5  bromo-4 
chloro-3 indolyl phosphate p-toluidine salt] and NBT [nitroblue 
tetrazolium chloride]; GIBCO BRL, Gaithersburg, MD). The color 
development was stopped by the addition of distilled water. The 
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cytosol mounting medium (Stephens  Scientific,  Riverdale,  NJ). 
Extracellular Matrix Protein Preparation 
BALB/c and DBA/2 heart tissue  extracellular biomatrix pro- 
teins were prepared according to the method described by P,  ojkind 
et al. (21). The protein concentration.was assayed  using a dye-binding 
assay of  protein quantitation (22) and stored at -20~  in glass tubes. 
Samples of extracellular matrix proteins were neutralized with 
Tris and heated for 10 rain at 90~  sample buffer in the presence 
of dithiothreitol (Calbiochem-Novabiochem Corp., La Jolla, CA). 
10 #tg of each sample were loaded in a 5~  SDS-PAGE minigel and 
run at 35 V for the stacking gel, 105 V for the running gel. SDS- 
PAGE gels were treated for 15 min in cold transfer buffer (2 mM 
Tris-HCl, 200 mM glycine, and 20~  methanol). The extraceUular 
matrix proteins were transferred to nitrocellulose (Schleicher  & 
Schuell, Inc.) at 35 V overnight at 4~  using a miniprotein transfer 
chamber (Bio-Rad Laboratories). The membrane was blocked with 
PBS-2% milk for 1 h at room temperature. The strips  were in- 
cubated with different monoclonal anti-myosin antibodies at 37~ 
for 2 h  and washed with PBS-0.05% Tween 20.  Immune com- 
plexes were developed using a peroxidase-labeled  goat anti-mouse 
lgG (Sigma Chemical Co.) and substrate (ECL Western blotting 
detection system). 
In each experiment, the gels were also stained  wtih 0.035% 
Coomassie brilliant blue, 45070 methanol, and 10% acetic acid over- 
night and destained  with 5070 acetic acetic  acid,  7070 methanol. 
Expression of Mouse Cardiac Myosin Heavy Chain Fragments 
The BALB/c myhca coding region was amplified in four seg- 
ments by reverse transcriptase  PCR from cardiac RNA. The fol- 
lowing primer pairs  were used:  Fragment, ATGACGGATGCC- 
CAGATG  and AGAAGTGGGCTTCCT (encoding amino acids 
1-562); fragment 2, AGGAAGCCCACTTCT and TTC'IGCAGC- 
TGAAG (encoding amino acids 562-1102); fragment 3, CTTCAG- 
CTGCAGAA and TCATGCTCCAGGGAG (encoding amino acids 
1102-1542); and fragment 4, CTCCCTGGAGCATGA and CAC- 
GATGAGGAATAA (encoding amino acids 1542-1972). 
Each of the PCR products was engineered to contain an in-frame 
NcoI site at the 5' end, a termination codon at the 3' end and a 
HindlII site. The fragments were cloned into the expression vector 
pMW172 at the NcoI and HindlII sites (23). For purification of 
the fragments, after isoprow1 thiogalacto-pyranoside IFIG induc- 
tion, 1-3 liters of bacterial culture was collected by centrifugation 
and lysed in the French press as previously described (23). For frag- 
ments 1 and 2, the insoluble pellet after lysis was solubilized  in 
a Sarkosyl extraction buffer (24) and further purified by prepara- 
tive acrylamide gel electrophoresis.  For fragments 3  and 4,  the 
soluble fraction after lysis was  subjected  to boiling. Myosin rod 
fragments will renature after this treatment, resulting in substan- 
tial purification (23). 
Results 
Serum Anti-myosin Response.  To determine  if there is a 
difference in the serum antibody response to myosin between 
BALB/c and DBA/2 mice, we examined titers of anti-myosin 
antibodies in serum of myosin-immunized mice. Anti-myosin 
reactivity  was  similar  in  myosin-immunized  DBA/2  and 
BALB/c mice. Fig. I shows that there was no significant differ- 
ence in titers oflgG anti-myosin antibodies in these two strains. 
Whereas antibodies of the IgG1, IgG2a, and IgG2b isotypes 
were present in both BALB/c and DBA/2 mice after immu- 
nization with autologous cardiac myosin (Fig.  2), BALB/c 
mice showed a significantly higher level of IgG1 anti-myosin 
antibodies. 
Fine specificity differences in anti-myosin antibodies  be- 
tween  these two strains  were assessed by assaying sera for 
reactivity to four genetically engineered fragments of BALB/c 
mouse myhca that span the molecule. As shown in Fig. 3, 
both BALB/c and DBA/2 sera showed reactivity to the en- 
tire length of the molecule, including fragment 2 (amino acids 
m 
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Figure  1.  BALB/c  and DBA/2 
mice were injected subcutaneously 
at four sites with 100/~g BALB/c 
cardiac myosin emulsified in CFA 
and boosted with  the  same im- 
munogen 7 d later. Serum samples 
were obtained 2 wk after the first 
immunization. Anti-myosin anti- 
bodies  were assayed by  ELISA. 
Briefly, 10/~g/ml of cardiac myosin 
was adsorbed to microtiter plates, 
blocked with  PBS-2% BSA, and 
then incubated  with serial dilutions 
of sera from immunized  mice. Anti- 
myosin reactivity  was detected  with 
peroxidase-conjugated  anti-mouse 
IgG diluted 1:1,000 (Sigma Chem- 
ical Co.) and substrate, 2,2,-, azino- 
di-3-ethylbenzt  hiazoline sulfonate. 
Optical density was read at 405 nm 
on an ELISA reader. Each line rep- 
resents an average of five mice. 563-1102).  This region was previously shown to be impor- 
tant  for induction  of autoimmune  myocarditis in BALB/c 
mice (25). BALB/c sera showed significantly higher reactivity 
to the rod region (fragments 3 and 4) of myhca. In contrast, 
DBA/2 mice showed higher binding to fragment 1 from the 
head region of myosin. Serologic studies, therefore, suggested 
a  difference in fine specificity of anti-myosin  antibodies  in 
cardiac myosin-immunized BALB/c and DBA/2 mouse sera, 
but showed no difference in reactivity to the intact myosin 
molecule. 
Characterization of Monoclonal Anti-myosin Antibodies and 
Antibody-mediatedDisease  Induction.  To explore whether differ- 
Figure 2.  BALB/c  and DBA/2 
mice  were  immunized  with BALB/c 
cardiac myosin as described  in Fig. 
1. Serum samples, obtained 2 wk 
after the first immunization, were 
assayed for subclass of anti-myosin 
antibodies. Each bar represents an 
average of five mice. 
ences in fine antigenic specificity might account for the differ- 
ence in pathogenicity, we generated monoclonal anti-myosin 
antibodies  from three susceptible strains  of mice,  DBA/2, 
BALB/c, and A.CA. Four IgG monodonal antibodies against 
different regions of myhca were selected for in vivo assays 
of disease induction.  Characteristics  of these antibodies are 
summarized  in Table 1.  Since BALB/c and  DBA/2  myhca 
alleles differ by a single amino acid at residue 545, serine and 
alanine, respectively (26), we verified by ELISA that the anti- 
myosin antibodies bound equally well to BALB/c and DBA/2 
cardiac myosin (Fig. 4).  Each of these four IgG antibodies 
was injected intraperitoneally into naive BALB/c and DBA/2 
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Figure 3.  Mice  were  immunized 
with BALB/c  cardiac  myosin  as de- 
scribed in Fig. 1.  Genetically en- 
gineered  BALB/c mouse myhca 
fragments were used to study the 
fine specificity  of IgG anti-myosin 
antibodies in BALB/c  and DBA/2 
mouse sera. These fragments were 
produced  in E. coli  as nonfusion  pro- 
teins using a modified pET vector 
system. The overexpressed  proteins 
were partially purified and eluted 
from  acrylamide  gels.  Anti- 
fragment reactivity was assayed  by 
ELISA. 10 gg/ml of  each fragment 
was adsorbed  to ELISA  plates. The 
ELISA was performed as described 
in Fig. 1 using serum at a 1:500 di- 
lution. Each bar represents an av- 
erage of three mice. Table  1.  Characterization  of Monoclonal Anti-myosin Antibodies 
Anti-myosin  Strain  Antigenic 
antibody  of origin  Isotype  specificity 
11C6-E3  A.CA  IgG2b  Head fragment  1 
11F7-C1  A.CA  IgG1  Rod  fragment  3 
2D6-B1  DBA/2  IgG2a  Head  fragment  2 
10D4-A9  BALB/c  IgG2a  Head fragment  1 
Monoclonal anti-myosin antibody-secreting hybridomas were generated 
from cardiac myosin-immunized A.CA, DBA/2, and BALB/c mice. Iso- 
types of anti-myosin antibodies were determined by ELISA. Antigenic 
specificity was determined using genetically engineered BALB/c mouse 
myhca fragments. 
mice. All four monoclonal anti-myosin antibodies caused dis- 
ease in DBA/2 mice (Table 2, Fig. 5) showing that antibody 
alone can induce myocarditis in a susceptible host.  In con- 
trast, no antibody caused disease  in BALB/c hearts. Since anti- 
myosin antibodies against both head and rod regions of  myhca 
can cause pathology in DBA/2 mice, it suggests that the fine 
specificity differences between BALB/c  and  DBA/2  anti- 
myosin responses cannot alone account for the difference in 
susceptibility to antibody-mediated disease seen in these two 
mouse strains. 
We next examined sections of hearts for the deposition 
of antibody. As shown in Fig. 6, DBA/2 mice showed marked 
IgG deposition in the affected hearts whereas BALB/c mice, 
which do not develop myocarditis after administration of the 
same anti-myosin antibody, showed little or no IgG deposi- 
tion. The Ig deposition seen in DBA/2 mice was not restricted 
to the area of necrosis and inflammation but was present 
throughout the heart. These studies demonstrate that there 
is a difference in the deposition of anti-myosin antibodies in 
BALB/c and DBA/2 hearts and that this difference  is associated 
with disease. 
Table  2.  Induction of Autoimmune Myocarditis in BALB/c, 
DBA/2,  and SCID Mice by Monoclonal Anti-myosin Antibodies 
Anti-myosin  Myocarditis  Myocarditis  Myocarditis 
antibody  DBA/2  BALB/c  SCID 
11C6-E3  5(5)  0(4)  0(4) 
11F7-Cl  5(6)  0(6)  0(4) 
2D6-B1  4(7)*  0(5)  0(5) 
10D4-A9  3(4)  0(5)  0(6) 
Hearts were scored for the presence of myocarditis (inflammation and 
myocyte necrosis) using the Dallas criteria (20). The numbers in paren- 
theses represent the number of mice injected. 
* The three remaining DBA/2 mice were  + / -  myocarditis (calcifica- 
tion and necrotic cells). Each mouse was injected intraperitoneally with 
purified anti-myosin antibody, 100/xg in 200 #1 PBS daily 5 d a week 
for 3 wk. Mice were killed after 3 wk. Formalin-fixed heart sections were 
stained with hematoxylin-eosin. 
To investigate whether clearance of anti-myosin antibody 
by anti-idiotypic  antibodies in BALB/c mice could account 
for this difference,  we employed  SCID mice that have a BALB/c 
genetic background. SCID mice have a defect in recombinase 
activity that blocks the development of mature T and B lym- 
phocytes, thereby precluding the possibility that endogenous 
anti-idiotypic antibodies were being elicited by the adminis- 
tration of anti-myosin antibody. SCID mice also showed no 
Ig deposition and no cardiac disease (Table 2, Fig. 6), demon- 
strating that the susceptibility to antibody-mediated autoim- 
mune disease  lies in the sensitivity of the heart to anti-myosin 
antibodies,  not in the antibodies  themselves. 
Analysis of Cardiac Extracellular Matrix.  To identify the 
antigen recognized by anti-myosin antibodies in DBA/2 hearts, 
we used monoclonal anti-myosin antibodies to probe Western 
blots of purified cardiac extracellular matrix proteins  (21). 
As seen  in Fig. 7, a monoclonal anti-sarcomeric myosin anti- 
body recognizes  a protein in DBA/2 extracellular matrix 
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Figure 4.  To compare the bind- 
ing  affinity of monoclonal  anti- 
myosin antibodies to BALB/c and 
DBA/2 myosin, titrations of anti- 
body were assayed by ELISA as de- 
scribed in Fig. 1. Figure 5.  (Left)  Heart section from a DBA/2 mouse injected with monoclonal anti-myosin antibody 2D6-B1. There is focal left ventricular myocel- 
lular necrosis and mononuclear  inflammation diagnostic of active myocarditis. Arrows identify sites of inflammation.  (Hematoxylin-eosin,  original, 
x200).  (Right)  Heart section from a DBA/2 mouse injected with monoclonal anti-myosin antibody 10D4-A9. There is a subepicardial left ventricular 
region of myocardial scarring with myocellular necrosis and calcification, and inflammation diagnostic of active myocarditis. Arrows identify sites of 
inflammation.  (Hematoxylin-eosin,  original,  x80). 
Figure 6.  Ig deposition in BALB/c, DBA/2, and SCID mouse hearts. BALB/c, DBA/2, and SCID mice were injected with purified monoclonal 
anti-myosin antibody in PBS. Paraffan-embedded  heart sections were deparafl~nized  and rehydrated, blocked with 2% normal goat serum (Vecta stain 
ABC Kit, Vector Laboratories, Inc.) in PBS in moist chambers. After blocking, the sections were incubated with biotinylated antibody against mouse 
IgG,  alkaline phosphatase-labeled avidin, (ABC reagent,  Vecta stain ABC Kit) and substrate. Figure  7.  Cardiac  extracellular  matrix  proteins  of  BALB/c  and DBA/2 
mouse  hearts  were  purified  according  to the method  described  by Rojkind 
et al. (21). 10 #g of each sample was displayed  on a 5% SDS-PAGE and 
stained  with Coomassie  blue or transferred  to nitrocellulose.  The nitrocel- 
lulose blots were  blocked with 5% milk  in PBS and incubated  with anti- 
myosin  antibody,  rabbit anti-fibronectin  antibody,  or rabbit anti-actin  an- 
tibody. After washing, blots were developed using a peroxidase-labeled 
goat antiserum to mouse  or rabbit IgG (Sigma Chemical  Co.) and sub- 
strate (ECL Western blotting detection system). 
Monoclonal anti-myosin antibodies specific for epitopes in 
either the myosin head or rod recognize this protein (data 
not shown). Because this protein has the same apparent mo- 
lecular weight as myosin heavy chain and is immunoreactive 
with all monoclonal anti-myosin antibodies tested, we be- 
lieve this protein may be myosin heavy chain. Alternatively, 
it may be a structurally homologous protein containing sev- 
eral shared antigenic determinants in common with myosin. 
This protein is present,  though in much smaller amounts 
(10-fold less), in cardiac  extracellular matrix from BALB/c 
mice. 
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We next examined whether the presence  of this protein 
was due to released intracellular proteins resulting from in- 
advertent destruction of myocytes during the preparation of 
extracellular matrix proteins. We probed the blots with anti- 
body to actin, as the presence of actin in extracellular matrix 
should reflect release of this protein from intact myocytes in 
the course of isolation of extracellular matrix proteins. As 
shown in Fig. 7,  the amount of actin present is the same 
in both strains.  The increased presence of myosin in DBA/2 
extracellular  matrix, therefore, cannot be due to differential 
fragility of DBA/2 and BALB/c myocytes. In addition, the 
amount of fibronectin, a known extracellular matrix protein 
is also the same in both preparations. 
Discussion 
It is clear that the genetics of autoimmune diseases is com- 
plex,  and that multiple genes can predispose  to autoimmu- 
nity. Many of the candidate genes that have been proposed 
to play a role in susceptibility to autoimmune disease encode 
proteins of importance within the immune system, in the 
induction or regulation of an immune response or in the clear- 
ance of antigen-antibody complexes.  It is evident, however, 
from studies  of human diseases and of animal models, that 
autoreactive  lymphocytes can be activated in some individ- 
uals, yet the individuals have no progression to autoimmune 
disease. Many studies (27,  28) have demonstrated the pres- 
ence of autoantibodies in the serum of relatives of individ- 
uals with autoimmune disease. Serologic studies suggest these 
autoantibodies have the structural characteristics  of patho- 
genic autoantibodies, yet they do not appear to cause disease. 
We have examined the molecular basis for susceptibility 
to anti-myosin antibody-mediated heart disease. BALB/c mice 
do not develop an antibody-mediated disease, whereas DBA/2 
mice do.  The data demonstrate that the two strains make 
equivalent anti-myosin antibody responses and that antibodies 
from either strain will cause disease in a susceptible host and 
will not cause disease in a resistant host. It has similarly been 
shown in rats that there is strain-specific susceptibility to the 
nephritis caused by antitubular basement membrane (TBM) 
antibody (29).  Brown  Norway rats  develop  an antibody- 
mediated disease, whereas Lewis rats show no deposition of 
anti-TBM antibody in kidneys and no nephritis. Whereas 
there appears to be no TBM antigen exposed in vivo in kidneys 
of Lewis rats, trypsin solubilization of renal TBM appears 
to expose the target antigen (30).  It is not known how the 
nephritogenic epitopes  are concealed  in the intact tissue of 
Lewis rats. 
The critical difference in target antigen exposure between 
the DBA/2 and the BALB/c heart appears to be that myosin, 
or a myosin-like protein, is present in substantially larger quan- 
tities in the extracellular matrix of DBA/2 hearts. The pres- 
ence of this protein in normal extracellular  matrix may ex- 
plain how antibody to a presumably intracellular antigen can 
cause disease in undamaged tissue. The reasons for its increased 
expression  in DBA/2 extracellular matrix are not known. 
If the protein is indeed myosin, the single amino acid differ- 
ence between BALB/c and DBA/2 myosin might be respon- sible for preferential trapping of DBA/2 myosin in extracel- 
lular  matrix.  Alternatively,  and  we  believe  more  likely, 
strain-specific differences in extracellular matrix proteins or 
in proteases that degrade myosin may underlie the sequestra- 
tion of myosin in DBA/2 hearts.  Finally, it is possible that 
myosin is processed differently in the two strains.  A recent 
study (31) shows that liver fat-storing cells can produce a 
muscle type of myosin that deposits in extracellular  matrix 
suggesting the possibility that myosin released from dying 
cells is binding to an extraceUular matrix protein or, less likely, 
that myosin is actively secreted into the extracellular matrix. 
This study demonstrates that anti-myosin antibodies alone 
are pathogenic in a susceptible host. The basis for the differen- 
tial sensitivity to anti-myosin antibodies in different mouse 
strains involves a genetically determined difference in target 
organ sensitivity to the same antibody. This observation sub- 
stantially alters our understanding of the genetics of murine 
autoimmune myocarditis. In humans, anti-myosin antibodies 
have been considered a marker of myocardial injury but have 
not been considered to have pathogenic potential. Our data 
raise the possibility that in some individuals a serum anti- 
myosin response  might contribute to cardiac injury. 
It will be important to study human cardiac tissue to see 
whether myosin or a myosin-like molecule is deposited in 
extracellular  matrix of individuals susceptible  to cardiac in- 
jury from anti-myosin antibody, Differential target organ sen- 
sitivity might help explain the genetic predisposition of cer- 
tain individuals to rheumatic fever as well as susceptibility 
to antibody-mediated cardiac damage after myocardial ischemia 
and other injuries to the heart. 
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